查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840821

GLP-1受體促效劑市場（按藥物類別、藥物類型、給藥途徑、應用和分銷管道）—全球預測 2025-2032

GLP-1 Receptor Agonist Market by Drug Class, Drug Type, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，GLP-1 受體促效劑市場將成長至 1,126.2 億美元，複合年成長率為 13.70%。

主要市場統計數據
基準年2024年 403.1億美元
預計2025年 455.9億美元
預測年份：2032年 1126.2億美元
複合年成長率（%） 13.70%

簡潔而全面地介紹 GLP-1 受體促效劑，這種革命性的藥物正在重塑治療策略和相關人員的決策。

GLP-1受體促效劑的出現和發展正在重塑代謝和循環系統醫學的治療方法，並推動藥物開發、製劑和給藥領域的快速創新。 GLP-1受體促效劑以其類似腸促胰島素的機製而聞名，其臨床討論正從血糖控制提升到更廣泛的終點，例如體重管理和心血管風險調節。因此，臨床、支付和商業相關人員在治療價值、患者可近性和長期療效的交叉領域面臨著更複雜的決策環境。

在此背景下，一份嚴謹的執行摘要旨在整合跨職能資訊並得出切實可行的結論。將產品層面的進展與監管趨勢、生產擴充性和不斷發展的通路相結合至關重要。從臨床試驗結果到日常實踐的過渡需要與臨床指南、報銷框架和患者依從性策略保持一致。後續章節將圍繞變革性轉變、與關稅相關的供應動態、細分資訊、區域觀點、競爭定位和實用建議進行組織，使讀者能夠獲得清晰的見解並採取行動。

深入探討改變 GLP-1 療法產品開發、患者照護途徑和商業策略的關鍵結構和臨床轉變

GLP-1受體促效劑領域正在經歷幾場變革，值得產業領袖和臨床醫生共同關注。首先，治療適應症不斷擴展。 GLP-1受體促效劑目前不僅用於血糖控制，還被用於減肥和降低代謝性心臟疾病風險，從而改變了臨床路徑和處方考量。同時，製劑科學的加速發展，導致長效和短效製劑之間出現分化，並催生了新的給藥模式，這些模式會影響患者的依從性和偏好。

其次，競爭和創新日益激烈，這得益於現有製藥公司不斷最佳化現有分子，以及新參與企業大力推廣差異化治療方法，包括口服胜肽和雙促效劑組合。這些競爭壓力正在推動一系列策略行動，例如擴大產品標籤、進行生命週期管理以及建立合作夥伴關係，以確保生產能力和分銷管道。第三，支付方和醫療系統正在重新評估價值框架，以平衡領先治療成本與降低併發症和提高醫療資源利用率等下游效益，從而促使更細緻的基於療效的合約和利用管理方法的出現。

最後，患者的期望和護理模式正轉向透過數位健康支援、遠端監控和協作護理團隊實現的綜合慢性病管理。這些變化凸顯了病患教育、依從性支持和真實世界證據生成的重要性。這些轉變並非孤立發生；它們將監管策略、臨床應用、商業性執行和供應鏈規劃緊密聯繫在一起，需要整個生態系統的相關人員做出全面回應。

分析 2025 年美國實施的關稅將如何加劇 GLP-1 治療供應鏈的複雜性、採購決策和商業性可行性

預計2025年實施的美國關稅政策和貿易措施將使GLP-1供應鏈更加複雜，影響採購決策、成本結構和策略規劃。儘管活性藥物原料藥和某些製劑投入品在全球分銷，但關稅將增加當地投入成本，並可能促使採購轉向關稅更優惠的地區。為此，企業正在重新評估其供應商佈局，評估近岸製造的擴張，並加快雙邊供應協議的簽訂，以降低進口關稅和物流波動帶來的風險。

此外，關稅帶來的成本壓力累積效應將與生技藥品和胜肽療法本已緊張的生產能力相互作用。製造商可能會根據其商業策略和合約義務優先安排生產分配，這可能會影響各分銷管道的產品供應和庫存規劃。付款人和醫療保健提供者的採購時機和成本回收策略可能會因此發生變化，製藥公司可能會尋求差異化定價演算法和基於價值的安排，以在控制利潤壓縮的同時保持市場准入。

重要的是，法規合規性和品質保證仍然是不可協商的限制因素，轉移生產基地或重新確認供應商需要時間和監管部門的參與。因此，採取積極主動的方法，結合採購多元化、策略性庫存緩衝以及與監管機構的密切溝通，可以減輕關稅帶來的干擾。那些在供應計劃中模擬關稅情景並及早投資替代採購和產能的公司，將能夠更好地保持供應的連續性，並保持臨床和商業性發展勢頭。

基於細分的關鍵洞察，揭示藥物類別、製劑類型、給藥途徑、治療用途和分銷管道如何決定策略重點

細分洞察揭示了藥物類別、藥物類型、給藥途徑、臨床應用和通路之間的差異化動態，這些動態決定了產品定位和生命週期優先順序。在藥物類別層面，像Dulaglutide、Liraglutide和Semaglutide這樣的成熟分子表現出獨特的臨床特徵和依證，這些特徵和循證基礎會影響指南整合和處方醫生偏好，進而影響通訊和醫療事務策略。在藥物類型層面，促效劑和短效促效劑的依從性模式、給藥便利性和產品組合權衡各不相同，這要求公司根據目標患者群體和護理環境調整製劑投資。

口服和腸外給藥製劑的採用曲線、病患接受度和藥局工作流程各不相同。口服製劑可以擴展到基層醫療，而腸外給藥通常需要結構化的臨床接觸點和培訓。心血管疾病、糖尿病管理和體重管理的應用細分產生了重疊但又各有差異的證據要求。心血管疾病適應症強調長期療效和減少事件發生，糖尿病管理以血糖指標和安全性為中心，而體重管理則優先考慮持續減重和生活品質終點。因此，臨床開發計劃和證據生成必須針對每種應用進行量身定做，以滿足不同的相關人員。

最後，不同的分銷管道——醫院、線上和零售——需要不同的商業模式。醫院藥房通常參與處方談判並向住院或專科診所銷售；線上藥房擁有以便利性為重點、直面患者的銷售管道，並提供依從性支持；零售藥房則提供廣泛的門診配藥服務，並提供照護現場教育機會。整合特定管道的物流、患者援助計劃和數位化互動策略，對於最大限度地提高醫療服務的連續性，並使商業性執行與臨床價值提案保持一致至關重要。

結合美洲、歐洲、中東和非洲以及亞太地區的監管、付款人和基礎設施差異的區域情報塑造了採用軌跡

GLP-1受體促效劑的區域動態受美洲、歐洲、中東和非洲以及亞太地區的法規環境、付款人架構和醫療保健服務模式的影響，每個地區都呈現出不同的採用路徑和營運考慮。在美洲，強力的臨床宣傳和心臟代謝適應症指南的快速整合加速了該藥物的採用，但由於報銷框架和付款人政策的差異性，需要有針對性地展示其價值和療效數據，以確保廣泛的可及性。因此，商業策略將強調真實世界證據和付款人參與，以將臨床效益轉化為受保的治療方法。

在歐洲、中東和非洲，一些相關人員通常優先考慮衛生經濟模型和區域性結果研究，以便為國家和地區報銷決策提供資訊。同時，在亞太地區，多樣化的監管途徑和快速發展的醫療保健投資既帶來了挑戰，也帶來了機會。圍繞糖尿病和肥胖症的公共衛生優先事項正在推動一些國家快速採用這些技術，而其他國家則因專家能力有限和負擔能力閾值差異而面臨限制。

在這些地區，供應鏈的彈性、腸外製劑的低溫運輸管理以及本地生產能力對執行效果至關重要。制定策略性區域規劃，將臨床開發時間表、監管申報和付款人參與與當地基礎設施實際情況相結合，對於最佳化上市順序並確保患者在多元化的醫療保健系統中持續獲得藥物至關重要。

競爭定位、策略聯盟、製造和監管重點的綜合視角決定了 GLP-1 療法公司層面的成功

GLP-1 領域的競爭和公司動態反映了製藥業穩固的領導地位以及日益壯大的服務供應商生態系統，這些舉措得到了大型研發機構和全球監管網路的支持，從而能夠產生先進的證據並影響指南。

除了大型製藥贊助商外，專業的契約製造、製劑開發商和技術合作夥伴在擴大胜肽生產規模以及開發穩定性和口服生物有效性解決方案方面也發揮關鍵作用。隨著企業尋求降低供應風險、加快臨床開發速度並同時維持質量，戰略聯盟和產能共用協議正變得越來越普遍。為了填補研發管線中的空白或確保互補的作用機制，企業之間也越來越常採用合併、授權協議和針對性授權等方式。

卓越的生產營運、敏捷的監管能力以及提供強大的上市後支援計畫的能力正逐漸成為企業脫穎而出的關鍵因素。那些將監管策略與生產規模擴張相結合，並投資於上市後證據生成的公司，將能夠更好地支持付款人談判和醫療機構的採用。此外，那些將臨床信譽與以患者為中心的服務（例如依從性工具和一體化護理路徑）相結合的公司，將能夠獲得持續的利用，並提升其治療方案的實際價值。

為行業領導者提供切實可行的建議，以保護管道價值，重點關注證據完整性、供應鏈彈性、特定管道的商業化和基於結果的契約

隨著GLP-1療法日益普及，產業領導者應採取一系列切實可行的舉措，以應對商業複雜性並保護其產品線的價值。首先，應儘早將臨床開發和證據產生與付款方和指南的要求相協調，並優先考慮對付款方、臨床醫生和患者都重要的結果。這種協調將縮短報銷決策的時間，並在療法顯示出超越替代終點的顯著現實世界益處時，支持其更廣泛的應用。

第二，透過多元化供應商、評估近岸製造能力、將關稅情境規劃納入採購流程，增強供應鏈的韌性。替代採購的前期投資將降低中斷風險，並維持產品上市和補貨的時效性。第三，設計能夠反映通路差異的分銷和病患支援模式。投資面向病患直銷通路的數位依從性工具，同時確保醫院和零售通路獲得量身訂做的教育和後勤支援。第四，尋求製劑創新的策略夥伴關係，以擴大目標患者群體，並提供口服和低劑量給藥方案，從而提高患者依從性。

最後，選​​擇性地實施基於結果的合約和風險分擔安排，以收集可靠的真實世界數據，證明長期效益。此類合約可以解決付款人對領先成本的擔憂，同時將商業性獎勵與持續的臨床結果相結合。將這些努力與嚴謹的投資組合優先排序和營運準備相結合，可以幫助組織最大限度地發揮治療效果，並在快速發展的市場環境中保持競爭優勢。

透明而嚴謹的調查方法結合了主要相關人員訪談、監管和臨床文獻分析以及情境檢驗，可提供可操作的情報

本執行綜合報告背後的調查方法整合了多種定性和定量分析方法，以確保獲得全面、可靠的洞察。主要研究包括對臨床醫生、付款人、採購專業人員和商業領袖的結構化訪談，以了解臨床實施、報銷談判和分銷執行中的決策促進因素。除了這些相關人員的討論之外，我們還對監管指南、臨床試驗註冊中心和同行評審文獻進行了系統性回顧，以繪製特定適應症的證據需求和安全性概況。

二次分析整合了公開的監管文件、產品標籤和藥物安全檢測訊息，以了解比較安全性和給藥方案。供應鏈和生產評估利用產能圖譜和供應商分析來評估風險敞口和短期擴展方案。研究結果透過與行業專家進行最後覆核和情境測試檢驗，以評估對關稅變化和監管時間表等政策變化的敏感性。

數據綜合著重於證據品質、可重複性以及觀察對臨床策略、生產計劃和商業性執行的實際意義。此調查方法結合相關人員的意見、文件分析和情境建模，提供以實證為基礎、以策略為導向、滿足決策需求的可操作情報。

結論性綜合報告強調，需要製定涵蓋開發、供應和商業化的綜合性、實證主導策略，以實現治療的潛力

總而言之，GLP-1受體促效劑這個治療類別正迅速從傳統的血糖管理擴展到更廣泛的心臟代謝治療領域，推動新的臨床模式和商業性需求。製劑創新、競爭態勢和不斷變化的付款人期望之間的相互作用，需要採取涵蓋臨床開發、監管參與、供應鏈策略和特定管道商業化的綜合方法。相關人員若能積極主動地將證據生成與付款人需求相結合，預測貿易政策的變化並實現供應管道多元化，並投資於患者支持和療效追蹤，將更有能力將臨床前景轉化為永續的治療效益。

由於不同地區和管道的採用路徑存在差異，因此，制定獨特的策略至關重要，既要利用全球臨床數據，也要尊重當地監管和報銷的實際情況。最終，成功取決於能否將科學差異化與營運準備和相關人員協作相結合，從而確保患者可及性、臨床結果和商業性可行性同步推進。本文摘要的見解為確定開發、生產和上市等職能部門的後續步驟提供了策略基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 口服小分子 GLP-1 受體促效劑的出現解決了患者依從性挑戰並擴大了市場進入
  • 迅速採用 GLP-1促效劑和 SGLT2 抑制劑聯合治療來增強第 2 型糖尿病的血糖控制
  • 加強現實世界證據的生成，證明 GLP-1 受體促效劑對心血管的益處超出血糖值
  • 開發下一代 GLP-1 類似物，透過延長半衰期和減少注射頻率來提高患者依從性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. GLP-1受體促效劑市場（依藥物類別）

  • Dulaglutide
  • Liraglutide
  • Semaglutide

9. GLP-1受體促效劑市場（依藥物類型）

  • 長效促效劑
  • 短效促效劑

10. GLP-1受體促效劑市場（依給藥途徑）

  • 口服
  • 腸外

第11章 GLP-1受體促效劑市場（依應用）

  • 心血管健康
  • 糖尿病管理
  • 體重管理

12. GLP-1受體促效劑市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

13. GLP-1受體促效劑市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. GLP-1受體促效劑市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. GLP-1受體促效劑市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Eli Lilly and Company
    • Sanofi
    • Novo-Nordisk A/S
    • AstraZeneca
    • Pfizer.Inc
    • Amgen, Inc.
    • Innovent Biologics, Inc.
    • PegBio Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
Product Code: MRR-B9334AD6C5EF

The GLP-1 Receptor Agonist Market is projected to grow by USD 112.62 billion at a CAGR of 13.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.31 billion
Estimated Year [2025] USD 45.59 billion
Forecast Year [2032] USD 112.62 billion
CAGR (%) 13.70%

A concise but comprehensive introduction framing GLP-1 receptor agonists as transformative agents reshaping therapeutic strategy and stakeholder decision-making

The emergence and evolution of GLP-1 receptor agonists have reshaped therapeutic approaches across metabolic and cardiovascular disciplines, prompting rapid innovation in drug development, formulations, and delivery. These agents, defined by their incretin-mimetic mechanisms, have pushed clinical conversations beyond glycemic control to broader endpoints such as weight management and cardiovascular risk modulation. As a result, stakeholders across clinical, payer, and commercial domains confront a more complex decision environment where therapeutic value, patient access, and long-term outcomes intersect.

In this context, a rigorous executive summary seeks to synthesize cross-functional intelligence into actionable conclusions. It is essential to contextualize product-level advances alongside regulatory trends, manufacturing scalability, and evolving distribution pathways. Transitioning from trial results to routine practice requires alignment across clinical guidelines, reimbursement frameworks, and patient adherence strategies, and therefore this introductory overview foregrounds those interdependencies while setting the stage for deeper analysis. By framing the subsequent sections around transformative shifts, tariff-related supply dynamics, segmentation intelligence, regional perspectives, competitive positioning, and pragmatic recommendations, readers are equipped to move from insight to implementation with clarity and purpose.

A detailed examination of the major structural and clinical shifts transforming product development, patient care pathways, and commercial strategies for GLP-1 therapies

The landscape for GLP-1 receptor agonists has undergone several transformative shifts that warrant attention from industry leaders and clinicians alike. First, therapeutic indications have broadened: these agents are now evaluated and adopted not only for glycemic control but also for weight reduction and cardiometabolic risk mitigation, which has altered clinical pathways and prescribing considerations. Concurrently, formulation science has accelerated, creating a divergence between long-acting and short-acting profiles and enabling new administration paradigms that influence adherence and patient preference.

Second, competition and innovation have intensified, driven by both incumbent pharmaceutical companies optimizing existing molecules and newcomers advancing differentiated modalities, including oral peptides and combination dual agonists. This competitive pressure has catalyzed strategic behavior such as label expansions, lifecycle management, and collaborations to secure manufacturing capacity and distribution reach. Third, payer and health systems are re-evaluating value frameworks to balance up-front therapeutic costs with downstream benefits in comorbidity reduction and health resource utilization, prompting more nuanced outcomes-based contracting and utilization management approaches.

Finally, patient expectations and care models are shifting toward integrated chronic disease management with digital health support, remote monitoring, and coordinated care teams. These changes amplify the importance of patient education, adherence support, and real-world evidence generation. Taken together, these shifts are not isolated; they interlink regulatory strategy, clinical adoption, commercial execution, and supply chain planning, demanding an integrated response from stakeholders across the ecosystem.

An analysis of how United States tariff measures introduced in 2025 compound supply chain complexity, sourcing decisions, and commercial continuity for GLP-1 therapies

Tariff policy and trade measures implemented by the United States in 2025 introduce a material layer of complexity to GLP-1 supply chains, affecting sourcing decisions, cost structures, and strategic planning. While active pharmaceutical ingredients and certain formulation inputs are globally dispersed, tariffs can increase landed input costs and incentivize sourcing pivots or geographies with tariff advantages. In response, companies are reassessing supplier footprints, evaluating near-shore manufacturing expansions, and accelerating bilateral supply agreements to limit exposure to import duties and logistics volatility.

Moreover, the cumulative impact of tariff-driven cost pressures interacts with already tight manufacturing capacity for biologics and peptide therapeutics. Manufacturers may prioritize production allocation based on commercial strategy and contractual obligations, which could affect product availability windows and inventory planning across distribution channels. Payers and providers may experience resultant shifts in procurement timing and cost recovery strategies, and pharmaceutical companies may pursue differential pricing algorithms or value-based arrangements to preserve access while managing margin compression.

Importantly, regulatory conformity and quality assurance remain non-negotiable constraints; relocation of manufacturing or requalification of suppliers requires time and regulatory engagement. Consequently, a proactive approach that blends procurement diversification, strategic inventory buffers, and close dialogue with regulatory authorities can mitigate tariff-induced disruption. Companies that model tariff scenarios within supply planning and that invest early in alternative sourcing or capacity will be better positioned to sustain continuity of supply and to preserve clinical and commercial momentum.

Key segmentation-driven insights revealing how drug class, formulation type, administration route, therapeutic application, and distribution channels determine strategic priorities

Segmentation insights reveal differentiated dynamics across drug class, drug type, route of administration, clinical application, and distribution pathways that shape product positioning and lifecycle priorities. Within drug class, established molecules such as Dulaglutide, Liraglutide, and Semaglutide exhibit distinct clinical profiles and evidence bases that inform guideline integration and prescriber preference, which in turn affect messaging and medical affairs strategies. At the drug type level, contrasting long-acting agonists versus short-acting agonists create divergent adherence patterns, dosing convenience considerations, and portfolio trade-offs, prompting firms to align formulation investments with targeted patient populations and care settings.

Route of administration remains a pivotal differentiator: oral versus parenteral options alter adoption curves, patient acceptance, and pharmacy workflow; oral formulations can expand reach into primary care, whereas parenteral deliveries often require structured clinical touchpoints and training. Application segmentation spanning cardiovascular health, diabetes management, and weight management generates overlapping yet distinct evidence requirements; cardiovascular indications emphasize long-term outcomes and event reduction, diabetes management centers on glycemic metrics and safety, and weight management prioritizes durable weight loss and quality-of-life endpoints. Therefore, clinical development plans and evidence generation must be tailored to each application to satisfy distinct stakeholders.

Finally, distribution channel nuances-hospital pharmacies, online pharmacies, and retail pharmacies-demand differentiated commercial models. Hospital pharmacies typically engage in formulary negotiation and inpatient or specialty clinic distribution, online pharmacies emphasize convenience and direct-to-patient channels with adherence support, and retail pharmacies serve broad outpatient dispensing with opportunities for point-of-care education. Integrating channel-specific logistics, patient support programs, and digital engagement strategies will be central to maximizing treatment persistence and aligning commercial execution with clinical value propositions.

Regional intelligence synthesizing regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption trajectories

Regional dynamics for GLP-1 receptor agonists are shaped by regulatory environments, payer architectures, and healthcare delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct adoption pathways and operational considerations. In the Americas, adoption has been accelerated by strong clinical advocacy and rapid guideline integration for cardiometabolic indications, yet reimbursement frameworks and heterogeneity in payer policies require targeted value demonstrations and outcomes data to secure broad access. Consequently, commercial strategies emphasize real-world evidence and payer engagement to translate clinical benefit into covered therapies.

Within Europe, Middle East & Africa, regulatory harmonization in some jurisdictions is counterbalanced by fragmented reimbursement landscapes and variable infrastructure for chronic disease management, requiring adaptive launch sequencing and local evidence generation. Stakeholders often prioritize health economic modeling and regional outcome studies to inform national and subnational reimbursement decisions. Meanwhile, in the Asia-Pacific region, diverse regulatory pathways and rapidly evolving healthcare investment create both challenges and opportunities; some countries show fast uptake driven by public health priorities around diabetes and obesity, while others face constraints from limited specialist capacity and different affordability thresholds.

Across these regions, supply chain resilience, cold-chain management for parenteral products, and local manufacturing capabilities factor heavily into execution. Strategic regional planning that aligns clinical development timelines, regulatory submissions, and payer engagement with local infrastructure realities will be critical for optimizing launch sequencing and ensuring sustained patient access across heterogeneous health systems.

An integrated view of competitive positioning, strategic alliances, and manufacturing and regulatory execution priorities that define company-level success in GLP-1 therapeutics

Competitive and corporate dynamics in the GLP-1 domain reflect a combination of established pharmaceutical leadership, targeted lifecycle optimization, and an expanding ecosystem of service providers focused on capacity and delivery innovation. Leading originator companies maintain deep clinical trial programs and broad regulatory experience, deploying strategies that include indication expansion, differentiated dosing regimens, and investment in oral and alternate delivery platforms. These initiatives are supported by substantial R&D operations and global regulatory footprints, enabling sophisticated evidence generation and guideline influence.

Alongside large pharmaceutical sponsors, specialized contract manufacturers, formulation developers, and technology partners play a critical role in scaling peptide production and developing stability and oral bioavailability solutions. Strategic alliances and capacity-sharing agreements have become common as companies seek to de-risk supply and accelerate time to clinic while preserving quality. Mergers, licensing deals, and targeted in-licensing of novel candidates are frequently used to fill pipeline gaps or to secure complementary mechanisms of action.

Operational excellence in manufacturing, regulatory agility, and the ability to deliver robust post-launch support programs have emerged as differentiators. Firms that coordinate regulatory strategy with manufacturing scale-up and who invest in post-marketing evidence generation can better support payer negotiations and provider adoption. Moreover, companies that couple clinical credibility with patient-centric services-such as adherence tools and integrated care pathways-are positioned to capture sustained utilization and to reinforce therapeutic value in real-world settings.

Actionable recommendations for industry leaders focused on evidence alignment, supply chain resilience, channel-specific commercialization, and outcome-based contracting to protect pipeline value

Industry leaders should adopt a set of pragmatic, actionable initiatives to navigate commercialization complexities and to protect pipeline value as GLP-1 therapies proliferate. First, align clinical development and evidence generation with payer and guideline requirements early, prioritizing outcomes that matter to payers, clinicians, and patients. This alignment reduces time to reimbursement decisions and supports broader adoption when therapies demonstrate compelling real-world benefits beyond surrogate endpoints.

Second, reinforce supply chain resilience by diversifying suppliers, evaluating near-shore manufacturing capacity, and integrating tariff scenario planning into procurement. Anticipatory investment in alternative sourcing reduces the risk of disruption and preserves launch and replenishment timelines. Third, design distribution and patient support models that reflect channel differences; invest in digital adherence tools for direct-to-patient channels, while ensuring hospital and retail pathways receive tailored educational and logistical support. Fourth, pursue strategic partnerships for formulation innovation, enabling oral or less frequent dosing options that expand addressable patient populations and improve adherence.

Finally, implement outcome-based contracting and risk-sharing arrangements selectively, using robust real-world data collection to demonstrate longitudinal benefits. These agreements can bridge payer concerns about upfront costs while aligning commercial incentives with sustained clinical outcomes. By combining these initiatives with disciplined portfolio prioritization and operational readiness, organizations can maximize therapeutic impact and sustain competitive advantage in a rapidly evolving landscape.

A transparent and rigorous research methodology combining primary stakeholder interviews, regulatory and clinical literature analysis, and scenario validation for actionable intelligence

The research methodology underpinning this executive synthesis integrates multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with clinicians, payers, procurement specialists, and commercial leaders to capture decision drivers across clinical adoption, reimbursement negotiation, and distribution execution. These stakeholder discussions were complemented by systematic reviews of regulatory guidance, clinical trial registries, and peer-reviewed literature to map indication-specific evidence needs and safety profiles.

Secondary analyses synthesized publicly available regulatory filings, product labels, and pharmacovigilance disclosures to understand comparative safety and dosing paradigms. Supply chain and manufacturing assessments leveraged capacity mapping and supplier profiling to evaluate risk exposure and options for near-term scale adjustments. Throughout, findings were validated through cross-checks with industry experts and by scenario testing to assess sensitivity to policy shifts, such as tariff changes and regulatory timelines.

Data synthesis emphasized evidence quality, reproducibility, and the practical implications of findings for clinical strategy, manufacturing planning, and commercial execution. By combining stakeholder input, documentary analysis, and scenario modeling, the methodology delivers actionable intelligence that is both empirically grounded and strategically oriented toward decision-making needs.

A conclusive synthesis emphasizing the need for integrated, evidence-driven strategies across development, supply, and commercialization to realize therapeutic potential

In conclusion, GLP-1 receptor agonists represent a class of therapeutics that has rapidly expanded beyond traditional glycemic management into broader cardiometabolic care, driving new clinical paradigms and commercial imperatives. The interplay of formulation innovation, competitive dynamics, and evolving payer expectations requires an integrated response across clinical development, regulatory engagement, supply chain strategy, and channel-specific commercialization. Stakeholders who proactively align evidence generation with payer needs, diversify supply pathways in anticipation of trade policy shifts, and invest in patient support and outcome tracking will be better positioned to translate clinical promise into sustainable therapeutic impact.

As adoption pathways diversify across regions and channels, tailored strategies that respect local regulatory and reimbursement realities while leveraging global clinical data will be essential. Ultimately, success will hinge on the ability to synchronize scientific differentiation with operational readiness and stakeholder alignment so that patient access, clinical outcomes, and commercial viability advance in tandem. The insights summarized here provide a strategic foundation to inform those decisions and to prioritize next steps across development, manufacturing, and market access functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of oral small-molecule GLP-1 receptor agonists addressing patient adherence challenges and expanding market access
  • 5.2. Rapid adoption of combination therapies pairing GLP-1 agonists with SGLT2 inhibitors for enhanced glycemic control in type 2 diabetes
  • 5.3. Intensification of real-world evidence generation demonstrating cardiovascular benefits of GLP-1 receptor agonists beyond glycemic outcomes
  • 5.4. Development of next-generation GLP-1 analogs with prolonged half-life and reduced injection frequency for improved patient compliance

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GLP-1 Receptor Agonist Market, by Drug Class

  • 8.1. Dulaglutide
  • 8.2. Liraglutide
  • 8.3. Semaglutide

9. GLP-1 Receptor Agonist Market, by Drug Type

  • 9.1. Long-Acting Agonists
  • 9.2. Short-Acting Agonists

10. GLP-1 Receptor Agonist Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. GLP-1 Receptor Agonist Market, by Application

  • 11.1. Cardiovascular Health
  • 11.2. Diabetes Management
  • 11.3. Weight Management

12. GLP-1 Receptor Agonist Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. GLP-1 Receptor Agonist Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. GLP-1 Receptor Agonist Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. GLP-1 Receptor Agonist Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eli Lilly and Company
    • 16.3.2. Sanofi
    • 16.3.3. Novo-Nordisk A/S
    • 16.3.4. AstraZeneca
    • 16.3.5. Pfizer.Inc
    • 16.3.6. Amgen, Inc.
    • 16.3.7. Innovent Biologics, Inc.
    • 16.3.8. PegBio Co., Ltd.
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
    • 16.3.10. Boehringer Ingelheim International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. GE